75 results on '"Nikolousis E"'
Search Results
2. Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT
3. Intestinal lymphoma—a review of the management of emergency presentations to the general surgeon
4. Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: A British Society of Blood and Marrow Transplantation study
5. Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT (Bone Marrow Transplantation, (2022), 57, 3, (416-422), 10.1038/s41409-021-01553-x)
6. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT (vol 57, pg 416, 2022)
7. Single centre experience of lenalidomide in multiply relapsed and or refractory lymphomas: 219
8. Single centre experience of managing patients with double hit lymphoma (DHL): 218
9. Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study
10. SINGLE CENTRE EXPERIENCE OF ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WHO HAVE PREVIOUSLY UNDERGONE AUTOLOGOUS HSCT FOR HAEMATOLOGICAL MALIGNANCY: PH-AB268
11. REDUCED INTENSITY ALLOGENEIC TRANSPLANTS OUTCOMES FOR HIGH RISK AML ARE FAVOURED BY ACQUISITION OF EARLY FULL DONOR T CELL CHIMERISM:SINGLE CENTER EXPERIENCE: PH-P301
12. Midazolam in conjunction with local anaesthesia is superior to Entonox in providing pain relief during bone marrow aspirate and trephine biopsy
13. Pretransplant Genetic Susceptibility: Clinical Relevance in Transplant-Associated Thrombotic Microangiopathy
14. Transplant outcomes are not affected by CMV serostatus in patients with acute graft-versus-host disease: P511
15. Graft-versus-leukaemia effect post fludarabine, melphalan and alemtuzumab reduced intensity allogeneic stem cell transplant in HIV-infected patient with acute myeloid leukaemia
16. Intestinal lymphoma—a review of the management of emergency presentations to the general surgeon
17. Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: A British Society of Blood and Marrow Transplantation study
18. Is Daily Lenograstim From Day +7 Of Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) Is As Effective As Pegfilgrastim In Patients With Myeloma?
19. Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia
20. Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes
21. Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study
22. Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data.
23. High-density lipoprotein cholesterol and multiple myeloma: A systematic review and meta-analysis.
24. Molecular Advances in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease.
25. Clonal evolution in adult TCF3::HLF-positive acute lymphoblastic leukemia undergoing stem cell transplantation.
26. Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper.
27. Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT.
28. Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT.
29. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT.
30. Adenoviral Subacute Focal Meningoencephalitis Complicating Polatuzumab, Bendamustine and Rituximab Chemo-Immunotherapy for Aggressive B-Cell Lymphoma.
31. Human papilloma virus (HPV)-associated lesions in a post-bone marrow transplant patient responding to HPV vaccination.
32. Nodular Lymphocyte Predominant Hodgkin Lymphoma With Aberrant Immunophenotype or Variant Histopathology: Insights From Case Series of Three Patients.
33. Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study.
34. Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations.
35. ERRATUM: A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplant.
36. COVID-19 in bone marrow transplant recipients: reflecting on a single centre experience.
37. First case of near haploid philadelphia negative B-Cell acute lymphoblastic leukaemia relapsing as acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.
38. Pretransplant Genetic Susceptibility: Clinical Relevance in Transplant-Associated Thrombotic Microangiopathy.
39. Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
40. Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation.
41. Autoimmune Cytopenias Developing Late Post Alemtuzumab-Based Allogeneic Stem Cell Transplantation: Presentation of Short Case Series from a Transplant Center.
42. Reduced intensity alemtuzumab-containing allogeneic stem cell transplantation for relapsed/refractory low grade lymphoma: reflections on a single center experience.
43. Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease.
44. Moving cancer care closer to home: a single-centre experience of home chemotherapy administration for patients with myelodysplastic syndrome.
45. A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplant.
46. Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.
47. Reduced intensity allogeneic stem cell transplant for treatment of blastic plasmacytoid dendritic cell neoplasm.
48. Two cases of aspergillus endocarditis in non neutropenic children on chemotherapy for acute lymphoblastic leukaemia.
49. Allogeneic transplant outcomes are not affected by body mass index (BMI) in patients with haematological malignancies.
50. Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.